Luxa Biotechnology's RPESC-RPE-4W transplantation received FDA's RMAT designation for treating dry AMD, highlighting its potential to address unmet patient needs. RPESC-RPE-4W is derived from adult ...
Clinical data from the Phase 1/2a clinical trial evaluating RPESC-RPE-4W was presented at the 77th Annual Wills Eye Conference in Philadelphia, Pennsylvania on March 6, 2025. The findings were from 6 ...
2 Department of Ophthalmology and Orthoptics, University of Sheffield, Sheffield, UK 3 Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK 4 Department of Histopathology, Royal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback